Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study-Reference-Cited by-同舟云学术

Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study

Published:2021-08 Issue:4 Volume:6 Page:100222
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Nannini M.^ORCID,Rizzo A.,Nigro M.C.,Vincenzi B.,Mazzocca A.,Grignani G.,Merlini A.,D’Ambrosio L.,Tolomeo F.,Badalamenti G.,Incorvaia L.,Bonasera A.,Fumagalli E.,Miliziano D.,Ligorio F.,Brunello A.,Chiusole B.,Gasperoni S.,Novelli M.,Pantaleo M.A.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference23 articles.

1. Clinical diagnosis of gastrointestinal stromal tumor (GIST): from the molecular genetic point of view;Wu;Cancers (Basel),2019

2. The story of imatinib in GIST – a journey through the development of a targeted therapy;Reichardt;Oncol Res Treat,2018

3. ESMO Guidelines Committee and EURACAN. Gastrointestinal stromal tumours: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up;Casali;Ann Oncol,2018

4. Emerging drugs for the treatment of gastrointestinal stromal tumors;Pilco-Janeta;Expert Opin Emerg Drugs,2021

5. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity;Wilhelm;Int J Cancer,2011

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence;Future Oncology;2024-06-11

2. Epidemiology, Pathology, Diagnosis, Prevention, and Management of GI Stromal Tumors and Other GI Sarcomas;Gastrointestinal Oncology ‐ A Critical Multidisciplinary Team Approach 2e;2024-01-23

3. KIT/PDGFRA Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort Study;The Oncologist;2023-07-18

4. Case Report: Should Regorafenib be prescribed as a continuous schedule in gastrointestinal stromal tumors? Three case reports on Regorafenib personalized schedule;Frontiers in Oncology;2023-05-31

5. Molecular Tailored Therapeutic Options for Advanced Gastrointestinal Stromal Tumors (GISTs): Current Practice and Future Perspectives;Cancers;2023-03-30